Patents Assigned to Wellstat Therapeutics Corporation
-
Patent number: 10934284Abstract: Amine compounds having activity against inflammation, fungi, unicellular parasitic microorganisms, and cancer are described. The compounds contain a monocyclic, bicyclic, or tricyclic aromatic ring having one, two, or three ring nitrogen atoms.Type: GrantFiled: February 26, 2019Date of Patent: March 2, 2021Assignee: Wellstat Therapeutics CorporationInventors: David M. Simpson, Dennis Bryan Zerby, Ming Lu, Reid W. Von Borstel, Rui Li, Julian Reading, Stephen Wolpe
-
Patent number: 10085957Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and Plasmodium falciparum-induced inflammation. In Formula I, t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. R6 is hydrogen, hydroxy, halo, alkyl having from 1 to 3 carbon atoms, alkoxy having from 1 to 3 carbon atoms, nitro, thio, alkylthio, or cyano. X is C(O) or NH(R8) wherein R8 is hydrogen or alkyl having from 1 to 3 carbon atoms; provided that when X is C(O), r is 0 and t is 0.Type: GrantFiled: October 14, 2016Date of Patent: October 2, 2018Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. Von Borstel
-
Patent number: 10030015Abstract: Amine compounds having activity against inflammation, fungi, unicellular parasitic microorganisms, and cancer are described. The compounds contain a monocyclic, bicyclic, or tricyclic aromatic ring having one, two, or three ring nitrogen atoms.Type: GrantFiled: January 31, 2014Date of Patent: July 24, 2018Assignee: Wellstat Therapeutics CorporationInventors: David M. Simpson, Dennis Bryan Zerby, Ming Lu, Reid W. von Borstel, Rui Li, Julian Reading, Stephen Wolpe, Nureddin Aman
-
Publication number: 20170209476Abstract: Uridine triacetate or other uridine prodrugs are used to treat genetic glycosylation disorders by administering them in an amount sufficient to raise plasma uridine in the to a level greater than 30 micromolar. They can be administered alone or in combination with a sugar whose transfer is defective in the glycosylation disorder being treated.Type: ApplicationFiled: August 19, 2015Publication date: July 27, 2017Applicant: Wellstat Therapeutics CorporationInventor: Reid W. VON BORSTEL
-
Patent number: 9428552Abstract: Stem cells are mobilized from bone marrow by administering an amount of Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 2) or Phe-Ala-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 3) effective to mobilize the stem cells. This is useful for promoting bodily tissue regeneration in a patient in need of tissue regeneration treatment. Alternatively, the mobilized stem cells can be collected for transplant.Type: GrantFiled: November 18, 2013Date of Patent: August 30, 2016Assignee: Wellstat Therapeutics CorporationInventors: Irena Tsyrlova, Fawn Petty, Reid W. von Borstel, Julian Reading, Jiong Pei, Joel Saydoff
-
Patent number: 9133073Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.Type: GrantFiled: June 18, 2013Date of Patent: September 15, 2015Assignee: Wellstat Therapeutics CorporationInventor: Shalini Sharma
-
Patent number: 9115072Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I or a pharmaceutically acceptable salt thereof. In Formula I m is 0, 1, 2, 3 or 4; n is 0 or 1; m+n is not more than 4; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R6 is hydrogen, methyl or ethyl and R12 is hydrogen or methyl, or R6 is hydroxy and R12 is hydrogen, or R6 is O and R12 is absent, or R6 and R12 together are —CH2CH2—. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R8 and R9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R11) wherein R11 is hydrogen or alkyl having from 1 to 3 carbon atoms.Type: GrantFiled: May 9, 2013Date of Patent: August 25, 2015Assignee: Wellstat Therapeutics CorporationInventors: James Dennen O'Neil, Michael K Bamat, Reid W von Borstel, Shalini Sharma, Ramachandran Arudchandran
-
Patent number: 8889724Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and Plasmodium falciparum-induced inflammation.Type: GrantFiled: March 4, 2013Date of Patent: November 18, 2014Assignee: Wellstat Therapeutics CorporationInventors: James Dennen O'Neil, Shalini Sharma, Ramachandran Arudchandran
-
Patent number: 8829058Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I or a pharmaceutically acceptable salt thereof. In Formula I m is 0, 1, 2, 3 or 4; n is 0 or 1; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R6 is hydrogen, O or hydroxyl. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R8 and R9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R11) wherein R11 is hydrogen or alkyl having from 1 to 3 carbon atoms.Type: GrantFiled: March 13, 2009Date of Patent: September 9, 2014Assignee: Wellstat Therapeutics CorporationInventors: James Dennen O'Neil, Michael K. Bamat, Reid W. von Borstel, Shalini Sharma, Ramachandran Arudchandran
-
Patent number: 8703991Abstract: A method for synthesizing (phenylalkyloxy)phenyl-oxobutanoic acid compounds is described. The corresponding (phenylalkyloxy)acylphenyl compound is halogenated, giving the alpha haloketone. The halide is displaced by the anion of a di-alkyl malonate to give a substituted malonic ester. Hydrolysis of the ester and decarboxylation of the diacid gives the desired product.Type: GrantFiled: November 3, 2009Date of Patent: April 22, 2014Assignee: Wellstat Therapeutics CorporationInventors: David D. Wirth, Richard Hudspeth
-
Publication number: 20140088006Abstract: Stem cells are mobilized from bone marrow by administering an amount of Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gin-Val (SEQ ID NO: 1) effective to mobilize the stem cells. This method is useful for promoting preservation, repair, or regeneration of bodily tissue, or revascularization, in a patient in need of such treatment. Alternatively, the mobilized stem cells can be collected for transplant.Type: ApplicationFiled: May 18, 2012Publication date: March 27, 2014Applicant: Wellstat Therapeutics CorporationInventors: Irena Tsyrlova, Fawn Petty, Reid W. Von Borstel, Julian Reading
-
Patent number: 8664433Abstract: The compound 4-[3-(2,6-Dimethylbenzyloxy)phenyl]-4-oxobutanoic acid (DPA) is synthesized from 1-[3-(2,6-Dimethylbenzyloxy)-phenyl]-ethanone (DPE) via the intermediate 4-[3-(2,6-Dimethylbenzyloxy)phenyl]-4-oxobulanoic acid ethyl ester (DPAE).Type: GrantFiled: May 4, 2009Date of Patent: March 4, 2014Assignee: Wellstat Therapeutics CorporationInventors: Jason P. Chinn, Robert J. Kaufman, Shalini Sharma, David Wirth
-
Publication number: 20130336949Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and Plasmodium falciparum-induced inflammation.Type: ApplicationFiled: March 4, 2013Publication date: December 19, 2013Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: James Dennen O'Neil, Shalini Sharma, Ramachandran Arudchandran
-
Publication number: 20130331452Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula (I). The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and Plasmodium falciparum-induced inflammation. In Formula I, t, q, r, R6, R7, X and A are as defined herein.Type: ApplicationFiled: September 6, 2011Publication date: December 12, 2013Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: Shalini Sharma, Reid W von Borstel
-
Patent number: 8604083Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.Type: GrantFiled: July 2, 2007Date of Patent: December 10, 2013Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. Von Borstel, Kirvin L. Hodge, Michael K. Bamat, Stephen D. Wolpe
-
Patent number: 8552062Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.Type: GrantFiled: September 27, 2006Date of Patent: October 8, 2013Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. von Borstel, Kirvin L. Hodge
-
Publication number: 20130259850Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I or a pharmaceutically acceptable salt thereof. In Formula I m is 0, 1, 2, 3 or 4; n is 0 or 1; m+n is not more than 4; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R6 is hydrogen, methyl or ethyl and R12 is hydrogen or methyl, or R6 is hydroxy and R12 is hydrogen, or R6 is O and R12 is absent, or R6 and R12 together are —CH2CH2—. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R8 and R9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R11) wherein R11 is hydrogen or alkyl having from 1 to 3 carbon atoms.Type: ApplicationFiled: May 9, 2013Publication date: October 3, 2013Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: James Dennen O'NEIL, Michael K. BAMAT, Reid W. von BORSTEL, Shalini SHARMA, Ramachandran ARUDCHANDRAN
-
Patent number: 8546448Abstract: A process for forming a solid electrolytic capacitor and an electrolytic capacitor formed by the process. The process includes: providing an anode wherein the anode comprises a porous body and an anode wire extending from the porous body; applying a thin polymer layer onto the dielectric, and forming a dielectric on the porous body to form an anodized anode; applying a first slurry to the anodized anode to form a blocking layer wherein the first slurry comprises a first conducting polymer with an median particle size of at least 0.05 ?m forming a layer of crosslinker on the blocking layer; and applying a layer of a second conducting polymer on the layer of crosslinker.Type: GrantFiled: September 15, 2011Date of Patent: October 1, 2013Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. von Borstel, Ramchandran Arudchandran, Rita O'Neil
-
Patent number: 8481595Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. The agent is a compound of Formula (I): wherein m is 0, 1, 2, 3, 4, 5, 6, 7 or 8; R1 is hydrogen or alkyl having from 1 to 3 carbon atoms; and R2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms.Type: GrantFiled: January 13, 2009Date of Patent: July 9, 2013Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. von Borstel
-
Publication number: 20130137629Abstract: Various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis can be treated with a compound selected from an incretin mimetic and a dipeptidyl peptidase IV inhibitor in combination with a Compound of Formula I or a pharmaceutically acceptable salt thereof Three of R1, R2, R3, R4 and R5 are hydrogen and the remainder are independently selected from the group consisting of hydrogen, halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; and m is 0, 2 or 4. R6 is hydrogen, O or hydroxy, and X is —OR7, wherein R7 is hydrogen or alkyl having from 1 to 3 carbon atoms; or R6 is hydrogen, and X is —NR8R9, wherein R8 is hydrogen or hydroxy and R9 is hydrogen, methyl or ethyl. When X is —NR8R9, hydroxy none of R1, R2, R3, R4 and R5 is hydroxy.Type: ApplicationFiled: January 24, 2013Publication date: May 30, 2013Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventor: WELLSTAT THERAPEUTICS CORPORATION